PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Targeted treatment can significantly reduce relapse in children with AML leukemia

Findings from nationwide study led by Children's Mercy researcher highlighted at American Society of Hematology Meeting

2013-12-08
(Press-News.org) Contact information: Jake Jacobson
jajacobson@cmh.edu
816-701-4097
Children's Mercy Hospital
Targeted treatment can significantly reduce relapse in children with AML leukemia Findings from nationwide study led by Children's Mercy researcher highlighted at American Society of Hematology Meeting The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML). Post-treatment relapse rates are a major indicator of potential for long-term survival in children with the disease.

The study (abstract #355) evaluated a total of 1,022 children averaging 10 years old at trial sites nationwide, led by Alan Gamis, MD, MPH, Associate Division Director, Section of Oncology at Children's Mercy Hospital in Kansas City. It will be highlighted in an oral presentation Monday, Dec. 9, at the American Society of Hematology annual meeting in New Orleans.

"Chemotherapy has limits. Particularly in children, increasing doses further can become too toxic for the patient while still not achieving the desired effect on the cancer," said Dr. Gamis. "This study is significant because it shows for the first time that this targeted treatment can augment the effects of chemotherapy in children and effectively reduce their risk of relapse. We found it was most effective in the patients most at risk."

Gemtuzumab was removed from the U.S. market in 2010 because the U.S. Food and Drug Administration determined the potential risks of the drug outweighed the potential benefits. Recent research with the compound has raised questions about whether that action may have been premature. This data supports recent findings in adults with AML that gemtuzumab reduced their risk of relapse when added to standard chemotherapy.

"This could be an important treatment option for critical patients," said Dr. Gamis. "Gemtuzumab appears to have a real impact in increasing the likelihood of long-term survival in high-risk patients."

In this study, patients were treated with gemtuzumab or a standard treatment regimen. Compared with standard regimens, the addition of gemtuzumab was associated with better disease-free survival (61 vs. 55%) and reduced relapse risk (33 vs. 41%). It did not significantly improve overall survival (74 vs. 70%).

### Chat Live with Dr. Gamis Dr. Gamis will discuss this study and answer questions about pediatric oncology from medical professionals, media and the public via Twitter at 1 p.m. Central (2 p.m. Eastern) on Friday, Dec. 20, through the @ChildrensMercy account. Join the conversation by including #cancerchat and @ChildrensMercy in tweets.

About Children's Mercy Hospital Children's Mercy, located in Kansas City, Mo., is one of the nation's top pediatric medical centers. The 354-bed hospital provides care for children from birth through the age of 21, and has been ranked by U.S. News & World Report as one of "America's Best Children's Hospitals" and recognized by the American Nurses Credentialing Center with Magnet designation for excellence in nursing services. Its faculty of 600 pediatricians and researchers across more than 40 subspecialties are actively involved in clinical care, pediatric research, and educating the next generation of pediatric subspecialists. For more information about Children's Mercy and its research, visit childrensmercy.org or download our mobile phone app CMH4YOU for all phone types. For breaking news and videos, follow us on Twitter, YouTube and Facebook. END


ELSE PRESS RELEASES FROM THIS DATE:

New insights into pathophysiology of sickle cell disease and thalassemia may help improve care

2013-12-08
New insights into pathophysiology of sickle cell disease and thalassemia may help improve care (NEW ORLEANS, December 8, 2013) – New research presented today during the 55th American Society of Hematology Annual Meeting and Exposition ...

Novel drug regimen can improve stem cell transplantation outcomes

2013-12-08
Novel drug regimen can improve stem cell transplantation outcomes Bortezomib (Velcade) reduces GVHD, boosts survival NEW ORLEANS— Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved ...

Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease

2013-12-08
Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease In lab studies, CHOP researchers reprogram gene expression, showing proof-of-concept for potential therapy Hematology researchers at The Children's Hospital ...

Survey: Knowledge about HPV vaccine effectiveness lacking

2013-12-08
Survey: Knowledge about HPV vaccine effectiveness lacking ATLANTA — Knowledge about the efficacy of the human papillomavirus (HPV) vaccine in preventing cervical cancer was lacking in the majority of survey respondents for whom the information ...

Certain genetic alterations may explain head and neck cancer survival disparities

2013-12-08
Certain genetic alterations may explain head and neck cancer survival disparities ATLANTA — Certain genetic alterations to the PAX gene family may be responsible for survival disparities seen between African-American and non-Latino white men ...

Genetic mutations and molecular alterations may explain racial differences in head and neck cancers

2013-12-08
Genetic mutations and molecular alterations may explain racial differences in head and neck cancers Study helps explain why 'survival gap' persists for African-Americans A team of scientists at Johns Hopkins and in Texas has identified a handful of genetic mutations ...

Age shouldn't limit access to transplants for MDS, study suggests

2013-12-08
Age shouldn't limit access to transplants for MDS, study suggests NEW ORLEANS— Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according ...

Rare cause of anemia in newborns often overlooked, research suggests

2013-12-08
Rare cause of anemia in newborns often overlooked, research suggests Scientists recommend testing for Pearson syndrome in patients with congenital anemia Some babies diagnosed with and treated for a bone marrow failure disorder, called Diamond Blackfan ...

T cell immunotherapy: Promising results in children and adults with leukemia

2013-12-07
T cell immunotherapy: Promising results in children and adults with leukemia Researchers from The Children's Hospital of Philadelphia and University of Pennsylvania harness engineered T cells to eliminate tumors in blood Nearly 90 percent of ...

High-tech gene-therapy advances offer hope for patients with hard-to-treat blood disorders

2013-12-07
High-tech gene-therapy advances offer hope for patients with hard-to-treat blood disorders (NEW ORLEANS, December 7, 2013) – A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients ...

LAST 30 PRESS RELEASES:

Metallic glass catalyst paves the way for efficient water splitting

After cardiac event, people who regularly sit for too long had higher risk of another event

Streaked slopes on Mars probably not signs of water flow, study finds

Cover crops may not be solution for both crop yield, carbon sequestration

Researchers take AI to “kindergarten” in order to learn more complex tasks

Glaciers will take centuries to recover even if global warming is reversed, scientists warn

Mayo Clinic discovery could mean more donor hearts by extending the preservation time

Faced with drought, fertilizer helps grasslands grow strong

Researchers discover why donor hearts fail in cold storage — and how to prevent it

Nimble dimples: Agile underwater vehicles inspired by golf balls

Family of parasite proteins presents new potential malaria treatment target

Study finds Reform voters more datable than Tories

National Poll: Some parents say they waited too long to stop pacifier use or thumb-sucking in children

New US$35M partnership to advance blood disorder therapies

Is understanding propaganda a necessary skill for modern democracy?

Under embargo: Robots learning without us? New study cuts humans from early testing

New film highlights the hidden impact of climate change on brain health

Conservation leaders challenge global economic systems that value ‘dead’ nature over living planet

A multidimensional diagnostic approach for COPD

Wearable sensor could be used to monitor OSA treatment response

Waitlist deaths dropped under new lung transplant allocation system

Methotrexate as effective as prednisone in pulmonary sarcoidosis

Waist-to-height ratio predicts heart failure incidence

Climate change increases severity of obstructive sleep apnea

USC, UCLA team up for the world’s first-in-human bladder transplant

Two out of five patients with heart failure do not see a cardiologist even once a year and these patients are more likely to die

AI-enabled ECG algorithm performs well in the early detection of heart failure in Kenya

No cardiac safety concerns reported with a pharmaceutically manufactured cannabidiol formulation

Scientists wash away mystery behind why foams are leakier than expected

TIFRH researchers uncover a mechanism enabling glasses to self-regulate their brittleness

[Press-News.org] Targeted treatment can significantly reduce relapse in children with AML leukemia
Findings from nationwide study led by Children's Mercy researcher highlighted at American Society of Hematology Meeting